finance

STAT New York Event
Biotech

Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict 

By Kate Sheridan

George Church
Biotech

Veritas, genetics company founded by George Church, suspends U.S. operations

By Kate Sheridan

Credit card in hand
First Opinion

Step aside, biomarkers. Look to the bank account for early signs of dementia

By Eric Chess

Pill vapor
Biotech

Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?

By Kate Sheridan

Pharmalot

Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival

By Ed Silverman

The State of Biotech
Biotech

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

By Kate Sheridan

D.C. Insight IMAGE
Politics

Biotech venture capitalists form a lobbying coalition to join the drug pricing debate 

By Nicholas Florko

Broad Institute signage
Biotech

Novo Nordisk’s parent company to launch research incubator in Boston

By Kate Sheridan

Nancy Pelosi
Politics

In a rare political move, prominent biotech venture capitalists speak out against Pelosi’s drug pricing bill

By Nicholas Florko

Jorge Conde Andreessen Horowitz
Biotech

When bio-Twitter greets a sincere thread with snark, what can a Silicon Valley VC say?

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

Post society molecule landscape
Biotech

It’s tiny biotechs — not big drug makers — that fear ‘nuclear winter’ from Pelosi’s drug pricing bill

By Nicholas Florko

Social network
Biotech

Social connections first, science second: How biotech’s recipe for success has its limits

By Kate Sheridan

Calculator close up
Opinions Plus

Early price setting, other market access planning is key for early-stage drug, device companies

By Christopher Leo, Christian Thienel, and Brendan Wang

David Hung
Biotech

Former Axovant CEO David Hung is back — leading a cancer biotech with hefty funding

By Kate Sheridan

Steven St. Peter
Biotech

The country’s only diabetes-focused venture fund brings on a new partner

By Kate Sheridan

Stock ticker
First Opinion

Specialization improves return on capital in the life sciences

By Teresa Leste and Peter Baxendell

Business

This is awkward: Genome editing startup Beam has competition — from one of its own cofounders

By Adam Feuerstein and Damian Garde

Pharmalot

Pharmalittle: Opioid trial underway as distributors try to settle; patients beg DEA to reconsider opioid production cuts

By Ed Silverman

Lots of people
Biotech

How Colorado firefighters, a Hawaiian charity, and TV writers are fueling the biotech boom

By Kate Sheridan

colored DNA sequencing
Business

Illumina confronts the innovator’s dilemma

By Matthew Herper

Changzhou Qianhong Biochemical
First Opinion

As tariffs affect the pharma industry, business strategies must evolve

By Roddy Martin

First Opinion

Trump’s trade war is hurting companies like mine — and the biotechnology industry

By Mahesh Narayanan

Pharmalot
Pharmalot

Catalyst stock dives, although the fledgling drug maker has no idea why

By Ed Silverman

biotech invest
Biotech

RA Capital launches Carnot, an incubator for early-stage biotechs

By Kate Sheridan

Ginkgo Bioworks 06
Biotech

Ginkgo Bioworks scores an eye-popping valuation with latest fundraise

By Jonathan Saltzman — Boston Globe

Christopher Reeve and his wife Dana
Business

Reeve Foundation to invest in paralysis-treatment companies, as more nonprofits act like VCs

By Rebecca Robbins

Pharmalot

Pharmalittle: Purdue bankruptcy sets tone for opioid cases; Sanders criticizes Biden for praising pharma

By Ed Silverman

Financial toxicity
First Opinion

Ease financial toxicity by putting electronic medical records to work

By Walter J. O’Donnell

Purdue Pharma headquarters
Business

Purdue Pharma, maker of OxyContin and other drugs, files for bankruptcy

By Andrew Joseph

Your daily dose of news in health and medicine

Privacy Policy